Health · 1 sources covering this

HHS confirms Americans with high-risk Ebola exposures will have access to experimental therapy

Americans who have high-risk exposures to Ebola in the current outbreak in Central Africa will have access to an experimental antibody treatment.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·2h ago
HHS confirms Americans with high-risk Ebola exposures will have access to experimental therapy
Americans who have high-risk exposures to Ebola in the current outbreak in Central Africa will have access to an experimental antibody treatment.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/d0e76457da62e40acd172cd3bd8f34de7555934d"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="HHS confirms Americans with high-risk Ebola exposures will have access to experimental therapy"></iframe>

HHS confirms Americans with high-risk Ebola exposures will have access to experimental therapy

How 1 sources are covering this

HHS confirms Americans with high-risk Ebola exposures will have access to experimental therapy

More from Health

STAT+: Drug companies, patient groups urge FDA to pause commissioner’s voucher program

Weakened public health powers raise outbreak risks

What RevMed’s pancreatic cancer drug meant for one patient

STAT+: Otsuka kidney drug slowed loss of function, but less than expected, in late-stage trial

Reader

Trust & legal

Across the network

How 1 sources are covering this

HHS confirms Americans with high-risk Ebola exposures will have access to experimental therapy

More from Health

STAT+: Drug companies, patient groups urge FDA to pause commissioner’s voucher program

Weakened public health powers raise outbreak risks

What RevMed&#8217;s pancreatic cancer drug meant for one patient

STAT+: Otsuka kidney drug slowed loss of function, but less than expected, in late-stage trial

Reader

Trust & legal

Across the network

What RevMed’s pancreatic cancer drug meant for one patient